

Ascletis begins two US Phase I studies of once-monthly obesity candidates

August 13, 2026 | News

The studies will evaluate ASC36, an amylin receptor peptide agonist, and ASC36_35 FDC, a co-formulation combining ASC36 with the GLP-1R/GIPR agonist ASC35.



Ascletis Pharma has initiated two Phase I studies in the United States evaluating investigational once-monthly injectable therapies for obesity.

The clinical programmes cover ASC36, a peptide amylin receptor agonist, and ASC36_35 FDC, a fixed-dose co-formulation combining ASC36 with ASC35, a peptide GLP-1R/GIPR agonist.

Both candidates form part of Ascletis' expanding pipeline of long-acting therapies targeting metabolic disease.

ASC36 is being developed as a long-acting amylin receptor agonist using Ascletis' ultra-long-acting drug development platform.

The company is also developing ASC36_35 FDC as a multi-mechanism obesity therapy targeting the amylin receptor, GLP-1 receptor and GIP receptor within a single monthly formulation.

Ascletis previously submitted investigational new drug applications to the US Food and Drug Administration for both programmes after completing preclinical development.

In preclinical diet-induced obesity models, the company reported that ASC36_35 FDC produced greater weight reduction than the combination of eloralintide and tirzepatide.

ASC36 was also evaluated against other investigational amylin-targeting therapies during preclinical development.

The two Phase I studies will provide initial clinical information on the candidates as Ascletis advances its portfolio of longer-acting obesity treatments.

Ascletis is also developing other metabolic disease candidates targeting GLP-1, GIP and glucagon-related pathways.